[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351539-105":59,"doc-detail-351539-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","brca1-promoter-cpg-methylation-in-breast-cancer-a-pilot-study-in-african-women","BRCA1 Promoter CpG Methylation in Breast Cancer - A Pilot Study in African Women","","Breast cancer susceptibility gene 1 (BRCA1) is central to DNA repair, and loss via germline mutations is linked to aggressive disease. Besides genetic disruption, promoter hypermethylation can epigenetically silence tumour suppressors and act as a biomarker. This study evaluates BRCA1 promoter methylation, gene expression impact, and associations with clinicopathological features in a cohort of African women with breast cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/brca1-promoter-cpg-methylation-in-breast-cancer-a-pilot-study-in-african-women/351539/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/brca1-promoter-cpg-methylation-in-breast-cancer-a-pilot-study-in-african-women/351539.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this pilot study?","Question",{"text":112,"@type":113},"To investigate BRCA1 promoter CpG methylation in breast cancer, its effects on BRCA1 gene expression, and its association with clinicopathological features in African women.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were BRCA1 promoter methylation and gene expression measured?",{"text":117,"@type":113},"Matched tumour and adjacent normal tissues from 27 Black African women were analyzed using bisulfite pyrosequencing for methylation and quantitative real-time PCR for gene expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings were observed about BRCA1 methylation?",{"text":121,"@type":113},"Five BRCA1 promoter CpG sites were hypermethylated in tumours versus matched normal tissue and inversely associated with BRCA1 mRNA expression. Methylation was enriched in hormone receptor-negative and triple-negative subtypes and was not affected by neoadjuvant chemotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351539,1790440418,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Article  \nBRCA1 Promoter CpG Methylation in Breast Cancer: A Pilot Study in African Women  \nTarryn Willmer 1,2,3, *, Mpoi Makhetha 4, Ayesha Rasheed Shaik 1,2, Lawrence Mabasa 1,2, Ines Buccimazza 5 and Colleen Aldous 4  \nAcademic Editor: Yutaka Suzuki  \nReceived: 4 February 2026  \nRevised: 10 March 2026  \nAccepted: 27 March 2026  \nPublished: 31 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa; [lawrence.mabasa@mrc.ac.za](lawrence.mabasa@mrc.ac.za) (L.M.)  \n2 Centre for Cardio-Metabolic Research in Africa, Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7505, South Africa  \n3 Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa  \n4 Department of Clinical Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4001, South Africa; mpoi.florence@gmail.com (M.M.); aldousc@ukzn.ac.za (C.A.)  \n5 Department of Oncology, Inkosi Albert Luthuli Central Hospital, Durban 4091, South Africa; [ines@orthoserve.co.za](ines@orthoserve.co.za)  \n* Correspondence: [tarryn.willmer@mrc.ac.za](tarryn.willmer@mrc.ac.za); Tel.: +27-219380269  \nAbstract  \nBackground: Breast cancer susceptibility gene 1 (BRCA1) is a pivotal regulator of DNA repair, and its loss through germline mutations is strongly linked to the development of aggressive breast cancers with characteristic clinical and pathological features. Beyond genetic disruption, epigenetic silencing via promoter hypermethylation has emerged as anon-mutational mechanism of tumour suppressor inactivation and a potential biomarker for guiding therapeutic decisions. Here, we investigate BRCA1 promoter methylation, its impact on gene expression, and its association with clinicopathological features in a cohort of African women with breast cancer. Methods: Matched tumour and adjacent normal tissues from 27 Black African women with breast cancer were analysed for BRCA1 promoter methylation and gene expression using bisulfite pyrosequencing and quantitative real-time PCR. Associations with clinicopathological variables were assessed using Spearman’s correlation analyses. Results: Five CpG sites within the BRCA1 promoter were significantly hypermethylated in breast tumours compared with matched adjacent normal tissues and showed an inverse association with BRCA1 mRNA expression. Elevated promoter methylation was enriched in hormone receptor-negative and triple-negative breast cancer subtypes and was not influenced by neoadjuvant chemotherapy. BRCA1 promoter methylation occurred independently of BRCA1 mutational status. No significant associations were observed between BRCA1 methylation and age, body mass index, smoking status, or alcohol consumption. Conclusions: Our findings provide evidence of BRCA1 epigenetic silencing in breast tumours from African women, particularly within aggressive hormone receptor-negative subtypes. These results suggest that BRCA1 promoter methylation may represent a clinically informative biomarker for patient stratification and highlight the importance of validation in larger, population-representative cohorts before clinical translation.  \nKeywords: epigenetic biomarkers; breast cancer; BRCA1; DNA methylation; Africans  \n1. Introduction  \nBreast cancer is the most commonly diagnosed malignancy among women worldwide and in Africa, and it remains a leading cause of cancer-related mortality. In 2022, approximately 2.3 million new cases were reported worldwide, with over 670,000 deaths attributed to the disease [1] . The global burden of breast cancer is expected to rise substantially, with annual new diagnoses projected to exceed ","cbCaihRIqUbJqdsO","https://ap.wps.com/l/cbCaihRIqUbJqdsO","pdf",1723530,16,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main objective of this pilot study?\",\"answer\":\"To investigate BRCA1 promoter CpG methylation in breast cancer, its effects on BRCA1 gene expression, and its association with clinicopathological features in African women.\"},{\"question\":\"How were BRCA1 promoter methylation and gene expression measured?\",\"answer\":\"Matched tumour and adjacent normal tissues from 27 Black African women were analyzed using bisulfite pyrosequencing for methylation and quantitative real-time PCR for gene expression.\"},{\"question\":\"What key findings were observed about BRCA1 methylation?\",\"answer\":\"Five BRCA1 promoter CpG sites were hypermethylated in tumours versus matched normal tissue and inversely associated with BRCA1 mRNA expression. Methylation was enriched in hormone receptor-negative and triple-negative subtypes and was not affected by neoadjuvant chemotherapy.\"}]","BRCA1 Promoter CpG Methylation in Breast Cancer - A Pilot Study in African Women | PDF",1790094639,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa62d1a5ed79c97956a2799b9f5d7b68.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b58abeec53b5894321337ffe3a5626f5.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3bf48f3f365d4ebd97a81c355a23200.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bf6bf0a150e19e92a09f51f33332612.webp",980,1385]